MedTrace Logo

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care

NCT05088928 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-10

No results posted yet for this study

Summary

The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care setting.

Conditions

Interventions

DRUG

Apixaban

Direct Acting Oral Anti coagulant

DRUG

Rivaroxaban

Direct Acting Oral Anti coagulant

Sponsors & Collaborators

  • Rawalpindi Medical College

    collaborator OTHER

  • Scotmann Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Prof. Dr. Muhammad Umar, MBBS · Rawalpindi Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-05-30
Completion
2022-08-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05088928 on ClinicalTrials.gov